NEW YORK — Real-world data demonstrated an extension of treatment intervals and positive safety results for aflibercept 8 mg and faricimab when used to manage retinal diseases, according to a presenter.
At the OSN New York Retina meeting, Rishi P. Singh, MD, of Mass General Brigham in Boston, said in a presentation that therapies are expected to yield fluid-free retinas, stable or improved vision and a reduced number of injections with little side effects. However, maintenance and disease control are more challenging in the real world than in clinical trials due to variables that include